铁缺乏症,贫血和心力衰竭患者的铁补充:一项人口水平研究
Muizz Wahid1,2, Sunjidatul Islam1, Nariman Sepehrvand1,2
1Canadian VIGOUR Centre, University of Alberta, Edmonton, AB, Canada (M.W., S.I., N.S., D.C.D., F.A.M., P.K., J.A.E.).
Circulation. Heart failure
|April 4, 2024
概括
在心力衰竭 (HF) 患者中,缺铁是常见的,但治疗往往不足于指导方针. 这项研究强调了在急性和慢性HF人群中需要更好的铁管理策略.
科学领域:
- 心脏病学 心脏病学
- 血液学 血液学 血液学
- 公共卫生 公共卫生
背景情况:
- 缺铁 (ID) 与心力衰竭 (HF) 的不良结果有关,而不考虑贫血.
- 目前在HF患者中治疗ID的治疗实践可能与既定指南不一致.
研究的目的:
- 在急性和慢性HF患者中调查ID和缺铁性贫血 (IDA) 的患病率.
- 检查这些患者群体的铁补充实践.
- 评估患者是否有资格参加正在进行的与HF铁疗法相关的临床试验.
主要方法:
- 利用来自加拿大阿尔伯塔省 (2012-2019) 成年HF患者的人口级数据.
- 将患者分类为急性或慢性HF,使用实验室标准定义ID和IDA.
- 确定了 AFFIRM-AHF,IRONMAN 和 HEART-FID 试验的资格.
主要成果:
- 在经过测试的HF患者中,ID (72.6%急性,73.9%慢性) 和IDA (51.4%急性,49.0%慢性) 的高患病率.
- 铁疗法给了41.8%的急性和40.5%的慢性HF患者与IDA,和19.9%-21.7%的ID患者没有贫血.
- 口服铁是最常见的治疗方法 (28.1%);大约一半的队列有资格参加主要的铁疗法试验.
结论:
- 对于HF患者的ID的研究和治疗方法与当前的指导方针有所不同.
- 对于HF患者的最佳铁管理,在护理方面存在很大的差距.
- 创新策略是必要的,以改善铁疗法利用率和高频率患者的治疗结果.
相关概念视频
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
424
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
424
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
81
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
81
01:23Assessment of the Cardiovascular System I: Subjective Data
323
A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
323
01:26Heart Failure Drugs: Inotropic Agents
578
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
578
01:22Heart Failure Drugs: Diuretics
370
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370